For decades, scientists pursued the p38a protein as a key to treating cancer, inflammation, and neurodegeneration — yet every promising drug fell short. A team at IRB Barcelona has now revealed why: the protein quietly inhabits a second, oxidized form, sealed shut by a disulfide bridge, that no existing database had ever recorded. Because researchers were always studying p38a under conditions that erased this hidden state, they were designing drugs against a target that, in living cells, sometimes does not exist as they imagined it. The incomplete map, not the destination, was the problem all
News-Medical.net
· Dec 19, 2023
· health
· 2 min de lectura
High
Verificación: Verificado
Scientists discover hidden inactive form of p38a protein, reshaping drug design strategy
◉
Health & Medicine
8252 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% coincidencia
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% coincidencia
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% coincidencia
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% coincidencia
Cobertura Relacionada
World Socialist Web Site · Aug 22
H5N1 avian flu spreads across Australia with 290 confirmed infections
Australia faces a rapidly spreading H5N1 avian flu outbreak with 290 confirmed infections across all states, threatening…
Devdiscourse · Aug 22 Congo's Bundibugyo Crisis: Health Attacks Threaten Economic Stability Beyond Medical ResponseWHO warns that violence and attacks on health facilities in eastern DRC's Bundibugyo outbreak threaten disease control a…
The Times of India · Aug 22 Reactor blast at Telangana pharma unit kills 2, injures 9A reactor blast at a pharmaceutical unit in Telangana's Yadadri Bhuvanagiri district killed two workers and injured nine…
Google News · Aug 22 Exercise-mimicking weight-loss pill clears first human trialsEnveda's ENV-308, a novel obesity drug designed to replicate exercise's biochemical effects, has successfully completed …
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
🌎
Biomedical discovery of p38a protein's oxidized form has no direct geopolitical implications; this is a scientific advancement in drug design methodology.
Escalation Risk
low
Confidence
HIGH
No geopolitical power dynamics affected. This is fundamental biomedical research with potential future pharmaceutical applications.
Lente Económico
📈
Discovery of inactive p38a protein form could redirect pharmaceutical R&D toward cancer/inflammation treatments, potentially unlocking a multi-billion dollar market segment after decades of failed drug development attempts.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Medical devices and diagnostics
Healthcare and hospital services
Contract research organizations (CROs)
Patients with cancer, chronic inflammation, and neurodegenerative diseases may eventually benefit from more effective treatments; however, drug development timelines are lengthy (10+ years), so near-term consumer impact is minimal.
Regulatory agencies (FDA, EMA) may need to update drug approval frameworks for p38a inhibitors based on this new protein conformation understanding; increased R&D funding for protein structure research may be justified through health policy initiatives.